Health technology assessment and reimbursement of pharmaceuticals in Italy

Health technology assessment and reimbursement of pharmaceuticals in Italy

The Italian healthcare system is historically structured by the difference in economic development between the northern and southern parts of this country. The Italian Medicines Agency (AIFA) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-li...

Full description

Bibliographic Details
Main Authors:	F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2019-07-01
Series:	Фармакоэкономика
Subjects:	health technology assessment drug provision governmental pharmaceuticals reimbursement italy
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/295

Similar Items

The health technology assessment system in Australia
by: V. V. Omelyanovskiy, et al.
Published: (2020-02-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
by: Michael Kossmeier, et al.
Published: (2021-08-01)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023-12-01)

Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status
by: N. Maniadakis, et al.
Published: (2017-05-01)

Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy
by: V. A. Lemeshko, et al.
Published: (2021-04-01)

Drug provision and health technology assessment in France
by: V. V. Omelyanovskiy, et al.
Published: (2020-04-01)

Analysis of changes in drug reimbursement based on the example of the limit groups containing beta-2 adrenergic drugs in Poland in the years 2012-2021
by: Piotr Zbigniew Rykowski, et al.
Published: (2022-06-01)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01)

Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market
by: Mihajlo B Jakovljevic
Published: (2014-03-01)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
by: Krzysztof Piotr Malinowski, et al.
Published: (2020-10-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019-11-01)

The timelines for the price and reimbursement authorization in Italy 2018–2020
by: Valentina Gallo, et al.
Published: (2022-12-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01)

Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?
by: Rawson NS, et al.
Published: (2017-11-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020
by: Paola Raimondo, et al.
Published: (2020-12-01)

The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea
by: Kyung-Bok Son
Published: (2020-05-01)

Stratified Medicine and Reimbursement Issues
by: Hans-Joerg eFugel, et al.
Published: (2012-10-01)

Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria
by: Georgi Iskrov, et al.
Published: (2016-02-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Budget impact of publicly reimbursed prescription medicines in The Republic of Srpska
by: Tamara ePetrusic, et al.
Published: (2015-09-01)

Alternativas a la distribución de medicamentos y su retribución Alternatives to pharmaceutical distribution and reimbursement
by: R. Meneu
Published: (2002-04-01)

Financial Consequences of the Act on Reimbursement of Medicines for the National Health Fund and Patients
by: Zofia Skrzypczak, et al.
Published: (2019-01-01)

The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making; Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling”
by: Hansoo Kim, et al.
Published: (2021-02-01)

Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies
by: Vivian Chen, et al.
Published: (2023-12-01)

Introduction of medical products into healthcare practice and costs reimbursement: European experience
by: V. V. Omelyanovsky, et al.
Published: (2018-08-01)

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
by: Louise Binder, et al.
Published: (2022-03-01)

Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
by: Naina R. Verghese, et al.
Published: (2019-01-01)

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
by: Ting Wang, et al.
Published: (2020-12-01)

Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries
by: Juan Carlos Rejon-Parrilla, et al.
Published: (2023-11-01)

Postgraduate Courses in Pharmaceutical Medicine in Italy
by: Domenico Criscuolo
Published: (2017-06-01)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
by: Krzysztof Piotr Malinowski, et al.
Published: (2018-11-01)

Reimbursement decision-making system in Poland systematically compared to other countries
by: Aneta Mela, et al.
Published: (2023-10-01)

Technological capability at the Brazilian official pharmaceutical laboratories
by: José Vitor Bomtempo Martins, et al.
Published: (2008-10-01)

The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy
by: Francesco Malandrini, et al.
Published: (2023-02-01)

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate
by: Elizabeth Docteur, et al.
Published: (2015-12-01)